Taysha Gene Therapies, Inc. (TSHA) |
|
0.68 -0.02 (-2.84%)
|
03-24 16:00 |
|
Open: |
0.683 |
Pre. Close: |
0.6999 |
|
High:
|
0.756 |
Low:
|
0.65 |
|
Volume:
|
559,429 |
Market Cap:
|
42(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:30:41 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.12  One year: 1.34 |
| Support: |
Support1: 0.64 Support2: 0.54 |
| Resistance: |
Resistance1: 0.95 Resistance2: 1.14 |
| Pivot: |
0.85 |
| Moving Average: |
MA(5): 0.71 MA(20): 0.89
MA(100): 1.68 MA(250): 2.79 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 7.7 %D(3): 10.1 |
| RSI: |
RSI(14): 25.3 |
| 52-week: |
High: 7.07 Low: 0.64 |
| Average Vol(K): |
3-Month: 532 (K) 10-Days: 388 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TSHA ] has closed above bottom band by 17.0%. Bollinger Bands are 20.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.76 - 0.76 |
0.76 - 0.77 |
|
Low:
|
0.64 - 0.65 |
0.65 - 0.65 |
|
Close:
|
0.67 - 0.68 |
0.68 - 0.69 |
|
Company Description |
|
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas. |
Headline News |
Thu, 23 Mar 2023
DelveInsight Highlights Major Advances, Transformative Therapies ... - Medgadget
Wed, 15 Mar 2023
Taysha Gene Therapies to Release Fourth Quarter and Full-Year ... - GlobeNewswire
Thu, 09 Feb 2023
Fmr Cuts Stake in Taysha Gene Therapies (TSHA) - Nasdaq
Wed, 01 Feb 2023
Premarket Mover: Taysha Gene Therapies Inc (TSHA) Down 21.95% - InvestorsObserver
Tue, 31 Jan 2023
Taysha Gene Therapies Provides Update on TSHA-120 Program in ... - GlobeNewswire
Mon, 19 Dec 2022
Taysha Gene Therapies names new CEO (NASDAQ:TSHA) - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
62 (M) |
| Shares Float |
37 (M) |
|
% Held by Insiders
|
39.8 (%) |
|
% Held by Institutions
|
24 (%) |
|
Shares Short
|
1,720 (K) |
|
Shares Short P.Month
|
926 (K) |
Stock Financials |
|
EPS
|
-3.81 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.65 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-54.8 |
|
Return on Equity (ttm)
|
-212.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.46 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-143 (M) |
|
Levered Free Cash Flow
|
-120 (M) |
Stock Valuations |
|
PE Ratio
|
-0.18 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.18 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.3 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
